

Anna M Czarnecka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3404548/publications.pdf>

Version: 2024-02-01

182
papers

3,629
citations

172386

29
h-index

197736

49
g-index

191
all docs

191
docs citations

191
times ranked

5659
citing authors

#	ARTICLE	IF	CITATIONS
1	Choosing the right cell line for renal cell cancer research. <i>Molecular Cancer</i> , 2016, 15, 83.	7.9	205
2	Molecular Biology of Osteosarcoma. <i>Cancers</i> , 2020, 12, 2130.	1.7	198
3	Mitochondrial chaperones in cancer: From molecular biology to clinical diagnostics. <i>Cancer Biology and Therapy</i> , 2006, 5, 714-720.	1.5	138
4	Targeted Therapy in Melanoma and Mechanisms of Resistance. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4576.	1.8	107
5	Three-dimensional cell culture model utilization in cancer stem cell research. <i>Biological Reviews</i> , 2017, 92, 1505-1520.	4.7	95
6	The role of the cell-cell interactions in cancer progression. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 283-296.	1.6	89
7	Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. <i>Cancer</i> , 2020, 126, 2637-2647.	2.0	86
8	Mitochondrial DNA mutations in human neoplasia. <i>Journal of Applied Genetics</i> , 2006, 47, 67-78.	1.0	75
9	Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: From the patient's bed to molecular mechanisms. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 31-41.	3.3	73
10	The Role of Hypoxia and Cancer Stem Cells in Renal Cell Carcinoma Pathogenesis. <i>Stem Cell Reviews and Reports</i> , 2015, 11, 919-943.	5.6	72
11	Mitochondrial NADH-dehydrogenase subunit 3 (ND3) polymorphism (A10398G) and sporadic breast cancer in Poland. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 511-518.	1.1	70
12	Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC). <i>Current Signal Transduction Therapy</i> , 2014, 8, 219-228.	0.3	67
13	Current approaches in identification and isolation of human renal cell carcinoma cancer stem cells. <i>Stem Cell Research and Therapy</i> , 2015, 6, 178.	2.4	57
14	Upon oxidative stress, the antiapoptotic Hsp60/procaspase-3 complex persists in mucoepidermoid carcinoma cells. <i>European Journal of Histochemistry</i> , 2008, 52, 221.	0.6	54
15	Insulin and IGFs in renal cancer risk and progression. <i>Endocrine-Related Cancer</i> , 2015, 22, R253-R264.	1.6	54
16	Heat shock protein 10 and signal transduction: a capsule of carcinogenesis?. <i>Cell Stress and Chaperones</i> , 2006, 11, 287.	1.2	50
17	Insulin-like growth factor-1 signaling in renal cell carcinoma. <i>BMC Cancer</i> , 2016, 16, 453.	1.1	49
18	Interleukin-6 as an emerging regulator of renal cell cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 476-485.	0.8	45

#	ARTICLE	IF	CITATIONS
19	The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory. <i>Current Pharmaceutical Design</i> , 2016, 22, 1756-1766.	0.9	43
20	Hormone signaling pathways as treatment targets in renal cell cancer (Review). <i>International Journal of Oncology</i> , 2016, 48, 2221-2235.	1.4	42
21	Balance between Transcription and RNA Degradation Is Vital for <i>Saccharomyces cerevisiae</i> Mitochondria: Reduced Transcription Rescues the Phenotype of Deficient RNA Degradation. <i>Molecular Biology of the Cell</i> , 2006, 17, 1184-1193.	0.9	36
22	Hsp60 and Hsp10 as antitumour molecular agents. <i>Cancer Biology and Therapy</i> , 2007, 6, 487-489.	1.5	36
23	Vitamin D receptor gene polymorphisms in breast and renal cancer: Current state and future approaches. <i>International Journal of Oncology</i> , 2014, 44, 349-363.	1.4	35
24	Renin angiotensin system deregulation as renal cancer risk factor (Review). <i>Oncology Letters</i> , 2017, 14, 5059-5068.	0.8	35
25	Choosing The Right Animal Model for Renal Cancer Research. <i>Translational Oncology</i> , 2020, 13, 100745.	1.7	35
26	Involvement of the CB2 cannabinoid receptor in cell growth inhibition and G0/G1 cell cycle arrest via the cannabinoid agonist WIN 55,212-2 in renal cell carcinoma. <i>BMC Cancer</i> , 2018, 18, 583.	1.1	34
27	Depressive-like neurochemical and behavioral markers of Parkinson's disease after 6-OHDA administered unilaterally to the rat medial forebrain bundle. <i>Pharmacological Reports</i> , 2017, 69, 985-994.	1.5	33
28	Frontiers in clinical and molecular diagnostics and staging of metastatic clear cell renal cell carcinoma. <i>Future Oncology</i> , 2014, 10, 1095-1111.	1.1	32
29	Mechanisms through which diabetes mellitus influences renal cell carcinoma development and treatment: A review of the literature. <i>International Journal of Molecular Medicine</i> , 2016, 38, 1887-1894.	1.8	32
30	Epithelioid Sarcoma—From Genetics to Clinical Practice. <i>Cancers</i> , 2020, 12, 2112.	1.7	32
31	CD1a downregulation in primary invasive ductal breast carcinoma may predict regional lymph node invasion and patient outcome. <i>Histopathology</i> , 2008, 52, 203-212.	1.6	31
32	Chondrosarcoma—from Molecular Pathology to Novel Therapies. <i>Cancers</i> , 2021, 13, 2390.	1.7	31
33	The Role of the Mitochondrial Genome in Ageing and Carcinogenesis. <i>Journal of Aging Research</i> , 2011, 2011, 1-10.	0.4	30
34	Surface markers of cancer stem-like cells of ovarian cancer and their clinical relevance. <i>Wspolczesna Onkologia</i> , 2018, 2018, 48-55.	0.7	30
35	Review Rhabdomyosarcoma of the head and neck in children. <i>Wspolczesna Onkologia</i> , 2015, 2, 98-107.	0.7	29
36	Insulin and insulin-like growth factors act as renal cell cancer intratumoral regulators. <i>Journal of Cell Communication and Signaling</i> , 2019, 13, 381-394.	1.8	29

#	ARTICLE	IF	CITATIONS
37	Comparative Gene Expression Profiling of Primary and Metastatic Renal Cell Carcinoma Stem Cell-Like Cancer Cells. PLoS ONE, 2016, 11, e0165718.	1.1	29
38	Mitochondrial genotype and breast cancer predisposition. Oncology Reports, 2010, 24, 1521-34.	1.2	26
39	Hsp60 and human aging: Les liaisons dangereuses. Frontiers in Bioscience - Landmark, 2013, 18, 626.	3.0	26
40	TP53 in Biology and Treatment of Osteosarcoma. Cancers, 2021, 13, 4284.	1.7	26
41	Hsp10 anatomic distribution functions and involvement in human disease. Frontiers in Bioscience - Elite, 2013, E5, 768-778.	0.9	25
42	Feasibility, efficacy and safety of tyrosine kinase inhibitor treatment in hemodialyzed patients with renal cell cancer: 10 years of experience. Future Oncology, 2015, 11, 2267-2282.	1.1	25
43	Gene set enrichment analysis and ingenuity pathway analysis of metastatic clear cell renal cell carcinoma cell line. American Journal of Physiology - Renal Physiology, 2016, 311, F424-F436.	1.3	25
44	Persistent Overexposure to N-Methyl-d-Aspartate (NMDA) Calcium-Dependently Downregulates Glutamine Synthetase, Aquaporin 4, and Kir4.1 Channel in Mouse Cortical Astrocytes. Neurotoxicity Research, 2019, 35, 271-280.	1.3	25
45	Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. Cancer, 2020, 126, 98-104.	2.0	25
46	Mitochondrial DNA mutations in cancer - from bench to bedside. Frontiers in Bioscience - Landmark, 2010, 15, 437.	3.0	24
47	Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities. Nature Reviews Urology, 2019, 16, 655-673.	1.9	24
48	Common mitochondrial polymorphisms as risk factor for endometrial cancer. International Archive of Medicine, 2009, 2, 33.	1.2	23
49	Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation. International Journal of Molecular Sciences, 2021, 22, 5077.	1.8	23
50	Diagnosis and treatment of malignant PEComa tumours. Oncology in Clinical Practice, 2020, 16, 22-33.	0.1	23
51	Management of pediatric head and neck rhabdomyosarcoma: A case-series of 36 patients. Oncology Letters, 2016, 12, 3555-3562.	0.8	22
52	Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells. Cell and Bioscience, 2017, 7, 71.	2.1	22
53	Molecular oncology focus - Is carcinogenesis a 'mitochondriopathy'?. Journal of Biomedical Science, 2010, 17, 31.	2.6	21
54	Aggressive osteoblastoma of the sphenoid bone. Oncology Letters, 2010, 1, 367-371.	0.8	20

#	ARTICLE	IF	CITATIONS
55	Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma. <i>Current Signal Transduction Therapy</i> , 2014, 8, 210-218.	0.3	20
56	Neoadjuvant Treatment Options in Soft Tissue Sarcomas. <i>Cancers</i> , 2020, 12, 2061.	1.7	20
57	Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6305.	1.8	20
58	Alterations in the expression of nNOS in the substantia nigra and subthalamic nucleus of 6-OHDA-lesioned rats: The effects of chronic treatment with L-DOPA and the nitric oxide donor, molsidomine. <i>Brain Research</i> , 2013, 1541, 92-105.	1.1	19
59	Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2014, 4, 194.	1.3	19
60	Chronic L-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra. <i>Behavioural Brain Research</i> , 2014, 261, 79-88.	1.2	19
61	Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma. <i>Future Oncology</i> , 2017, 13, 31-49.	1.1	19
62	Imaging of Uveal Melanoma—Current Standard and Methods in Development. <i>Cancers</i> , 2022, 14, 3147.	1.7	19
63	The role of prostaglandin E2 in renal cell cancer development: future implications for prognosis and therapy. <i>Future Oncology</i> , 2014, 10, 2177-2187.	1.1	18
64	Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice. <i>Targeted Oncology</i> , 2019, 14, 729-742.	1.7	18
65	Breast cancer as a mitochondrial disorder (Review). <i>Oncology Reports</i> , 2009, 21, 845-51.	1.2	17
66	Metastasis-Initiating Cells in Renal Cancer. <i>Current Signal Transduction Therapy</i> , 2014, 8, 240-246.	0.3	17
67	Development of extracellular matrix supported 3D culture of renal cancer cells and renal cancer stem cells. <i>Cytotechnology</i> , 2019, 71, 149-163.	0.7	17
68	Renal carcinoma CD105 ⁺ /CD44 ⁺ cells display stem-like properties in vitro and form aggressive tumors in vivo. <i>Scientific Reports</i> , 2020, 10, 5379.	1.6	17
69	Mitochondrial NADH-dehydrogenase polymorphisms as sporadic breast cancer risk factor. <i>Oncology Reports</i> , 2010, 23, 531-5.	1.2	17
70	Ovarian cancer as a genetic disease. <i>Frontiers in Bioscience - Landmark</i> , 2013, 18, 543.	3.0	16
71	Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer. <i>Future Oncology</i> , 2015, 11, 17-26.	1.1	16
72	Colony, hanging drop, and methylcellulose three dimensional hypoxic growth optimization of renal cell carcinoma cell lines. <i>Cytotechnology</i> , 2017, 69, 565-578.	0.7	16

#	ARTICLE	IF	CITATIONS
73	Functional significance of CD105-positive cells in papillary renal cell carcinoma. <i>BMC Cancer</i> , 2017, 17, 21.	1.1	16
74	Obstructive sleep apnea and cancer: effects of intermittent hypoxia?. <i>Future Oncology</i> , 2015, 11, 3285-3298.	1.1	15
75	Feasibility and Long-Term Efficacy of PEComa Treatmentâ€”20 Years of Experience. <i>Journal of Clinical Medicine</i> , 2021, 10, 2200.	1.0	15
76	Asymmetric Dimethylarginine and Hepatic Encephalopathy: Cause, Effect or Association?. <i>Neurochemical Research</i> , 2017, 42, 750-761.	1.6	14
77	BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma. <i>Melanoma Research</i> , 2020, 30, 465-471.	0.6	14
78	Combined Preoperative Hypofractionated Radiotherapy With Doxorubicin-Ifosfamide Chemotherapy in Marginally Resectable Soft Tissue Sarcomas: Results of a Phase 2 Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1053-1063.	0.4	14
79	Mitochondrial genotype in vulvar carcinoma - cuckoo in the nest. <i>Journal of Biomedical Science</i> , 2010, 17, 73.	2.6	13
80	Laryngeal embryonal rhabdomyosarcoma in an adult - A case presentation in the eyes of geneticists and clinicians. <i>BMC Cancer</i> , 2011, 11, 166.	1.1	13
81	^{99m} Tc octreotide scintigraphy and somatostatin receptor subtype expression in juvenile nasopharyngeal angiofibromas. <i>Head and Neck</i> , 2011, 33, 1739-1746.	0.9	13
82	Future perspectives for mTOR inhibitors in renal cell cancer treatment. <i>Future Oncology</i> , 2015, 11, 801-817.	1.1	13
83	The significance of rotational behavior and sensitivity of striatal dopamine receptors in hemiparkinsonian rats: A comparative study of lactacystin and 6-OHDA. <i>Neuroscience</i> , 2017, 340, 308-318.	1.1	13
84	Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy. <i>Cancers</i> , 2020, 12, 3131.	1.7	13
85	Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 723-742.	1.1	13
86	Mutation profile of primary subungual melanomas in Caucasians. <i>Oncotarget</i> , 2020, 11, 2404-2413.	0.8	13
87	Review Biology of renal tumour cancer stem cells applied in medicine. <i>Wspolczesna Onkologia</i> , 2015, 1A, 44-51.	0.7	12
88	Tyrosine kinase inhibitors target cancer stem cells in renal cell cancer. <i>Oncology Reports</i> , 2016, 35, 1433-1442.	1.2	12
89	Triiodothyronine regulates cell growth and survival in renal cell cancer. <i>International Journal of Oncology</i> , 2016, 49, 1666-1678.	1.4	12
90	OC-0069 5x5 Gy with chemotherapy in borderline resectable soft tissue sarcomas: early results of a trial. <i>Radiotherapy and Oncology</i> , 2019, 133, S31-S32.	0.3	12

#	ARTICLE	IF	CITATIONS
91	Metastatic renal cell carcinoma cells growing in 3D on poly-L-lysine or laminin present a stem-like phenotype and drug resistance. <i>Oncology Reports</i> , 2019, 42, 1878-1892.	1.2	12
92	Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence. <i>Advances in Medical Sciences</i> , 2020, 65, 316-323.	0.9	12
93	Efficacy of Sirolimus Treatment in PEComa – 10 Years of Practice Perspective. <i>Journal of Clinical Medicine</i> , 2021, 10, 3705.	1.0	12
94	Tracheal adenoid cystic carcinoma mimicking a thyroid tumor: A case report. <i>Oncology Letters</i> , 2014, 8, 1312-1316.	0.8	11
95	Three-Dimensional Cell Culture Model Utilization in Renal Carcinoma Cancer Stem Cell Research. <i>Methods in Molecular Biology</i> , 2018, 1817, 47-66.	0.4	11
96	Clinical and molecular prognostic and predictive biomarkers in clear cell renal cell cancer. <i>Future Oncology</i> , 2014, 10, 2493-2508.	1.1	10
97	Renal cell carcinoma with intramyocardial metastases. <i>BMC Urology</i> , 2014, 14, 73.	0.6	10
98	Intracerebral Administration of S-Adenosylhomocysteine or S-Adenosylmethionine Attenuates the Increases in the Cortical Extracellular Levels of Dimethylarginines Without Affecting cGMP Level in Rats with Acute Liver Failure. <i>Neurotoxicity Research</i> , 2017, 31, 99-108.	1.3	10
99	Treatment outcomes in older patients with advanced gastrointestinal stromal tumor (GIST). <i>Journal of Geriatric Oncology</i> , 2018, 9, 520-525.	0.5	10
100	Metastatic Tumor Burden and Loci as Predictors of First Line Sunitinib Treatment Efficacy in Patients with Renal Cell Carcinoma. <i>Scientific Reports</i> , 2019, 9, 7754.	1.6	10
101	Clinicopathological Features and Prognostic Factors of Primary Acral Melanomas in Caucasians. <i>Journal of Clinical Medicine</i> , 2020, 9, 2996.	1.0	10
102	The Management of Radiation-Induced Sarcomas: A Cohort Analysis from a Sarcoma Tertiary Center. <i>Journal of Clinical Medicine</i> , 2021, 10, 694.	1.0	10
103	Molecular basis of carcinogenesis in diabetic patients (Review). <i>International Journal of Oncology</i> , 2015, 46, 1435-1443.	1.4	9
104	Decreased behavioral response to intranigally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: Comparison to the classical neurotoxin 6-OHDA. <i>Behavioural Brain Research</i> , 2015, 283, 203-214.	1.2	9
105	High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors. <i>Melanoma Research</i> , 2018, 28, 435-441.	0.6	9
106	Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Follicular Differentiation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4759.	1.8	9
107	Systemic Treatment for Advanced and Metastatic Malignant Peripheral Nerve Sheath Tumors – A Sarcoma Reference Center Experience. <i>Journal of Clinical Medicine</i> , 2020, 9, 3157.	1.0	9
108	Thyroid Hormones as Renal Cell Cancer Regulators. <i>Journal of Signal Transduction</i> , 2016, 2016, 1-8.	2.0	8

#	ARTICLE	IF	CITATIONS
109	Prolonged complete response following gemcitabine-erlotinib combined therapy in advanced pancreatic cancer. <i>Oncology Letters</i> , 2016, 11, 1101-1104.	0.8	8
110	Molecular biology of sarcoma. <i>Oncology in Clinical Practice</i> , 2019, 14, 307-330.	0.1	8
111	Czerniak skł ³ ry. <i>Oncology in Clinical Practice</i> , 2020, 16, 163-182.	0.1	8
112	New Perspectives for Eye-Sparing Treatment Strategies in Primary Uveal Melanoma. <i>Cancers</i> , 2022, 14, 134.	1.7	8
113	Serum EPO and VEGF levels in patients with sleep-disordered breathing and acute myocardial infarction. <i>Sleep and Breathing</i> , 2013, 17, 1063-1069.	0.9	7
114	The use of sunitinib in renal cell carcinoma: where are we now?. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 983-999.	1.1	7
115	Radiotherapy in the Management of Pediatric and Adult Osteosarcomas: A Multi-Institutional Cohort Analysis. <i>Cells</i> , 2021, 10, 366.	1.8	7
116	What is the best front-line approach in patients with desmoid fibromatosis? – A retrospective analysis from a reference center. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2602-2608.	0.5	7
117	Efficacy of immunotherapy beyond RECIST progression in advanced melanoma: a real-world evidence. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1949-1958.	2.0	7
118	Impaired glucose metabolism treatment and carcinogenesis. <i>Oncology Letters</i> , 2015, 10, 589-594.	0.8	6
119	Endoglin Expression and Microvessel Density as Prognostic Factors in Pediatric Rhabdomyosarcoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 512.	1.0	6
120	First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland. <i>Immunotherapy</i> , 2021, 13, 297-307.	1.0	6
121	Biological Heterogeneity of Chondrosarcoma: From (Epi) Genetics through Stemness and Deregulated Signaling to Immunophenotype. <i>Cancers</i> , 2021, 13, 1317.	1.7	6
122	Doxorubicin plus dacarbazine (DoDa), doxorubicin plus ifosfamide (DI) or doxorubicin alone (Do) as first line treatment for advanced leiomyosarcoma (LMS): A retrospective study from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11574-11574.	0.8	6
123	Renal Cell Carcinoma Cancer Stem Cells as Therapeutic Targets. <i>Current Signal Transduction Therapy</i> , 2014, 8, 203-209.	0.3	6
124	Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients – Real-World Evidence. <i>Journal of Clinical Medicine</i> , 2022, 11, 2239.	1.0	6
125	Effects of cell-cell crosstalk on gene expression patterns in a cell model of renal cell carcinoma lung metastasis. <i>International Journal of Oncology</i> , 2017, 52, 768-786.	1.4	5
126	Pazopanib in Patients with Clear-Cell Renal Cell Carcinoma: Seeking the Right Patient. <i>Frontiers in Pharmacology</i> , 2017, 8, 329.	1.6	5

#	ARTICLE	IF	CITATIONS
127	An update on the safety of nivolumab for the treatment of advanced melanoma. Expert Opinion on Drug Safety, 2020, 19, 409-421.	1.0	5
128	Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma. Journal of Dermatological Treatment, 2022, 33, 2168-2174.	1.1	5
129	Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF V600 Mutation-Positive Melanoma. Cancers, 2022, 14, 110.	1.7	5
130	Vulvar cancer as a target for molecular medicine. Frontiers in Bioscience - Scholar, 2011, S3, 136-144.	0.8	4
131	Immuno-oncology for renal cell carcinoma treatment: future perspectives for combinations and sequences with molecularly targeted agents. Expert Opinion on Biological Therapy, 2017, 17, 151-162.	1.4	4
132	Cardiac safety of systemic therapy in breast cancer patients with high risk of atherosclerosis complications. Future Oncology, 2017, 13, 593-602.	1.1	4
133	Culture in embryonic kidney serum and xeno-free media as renal cell carcinoma and renal cell carcinoma cancer stem cells research model. Cytotechnology, 2018, 70, 761-782.	0.7	4
134	Cerebrovascular reactivity and cerebral perfusion of rats with acute liver failure: role of L-glutamine and asymmetric dimethylarginine in L-arginine-induced response. Journal of Neurochemistry, 2018, 147, 692-704.	2.1	4
135	Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in patients with advanced gastrointestinal stromal tumors treated with sunitinib after imatinib failure. Oncology Letters, 2019, 18, 3373-3380.	0.8	4
136	Malignant peripheral nerve sheath tumors – Outcomes and prognostic factors based on the reference center experience. Surgical Oncology, 2020, 35, 276-284.	0.8	4
137	Malignant peripheral nerve sheath tumour (MPNST). Oncology in Clinical Practice, 2019, 14, 364-376.	0.1	4
138	Rozpoznanie i leczenie nowotworów typu angiomyolipoma (AML). Oncology in Clinical Practice, 2020, 16, 116-132.	0.1	4
139	Snoring but not BMI influences aggressive behavior and concentration problems in children. Otolaryngologia Polska, 2015, 69, 21-25.	0.2	4
140	Mitochondrial DNA Mutations in Tumors. , 2009, , 119-130.		4
141	Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients. Melanoma Research, 2021, 31, 49-57.	0.6	4
142	Treatment of Malignant Adnexal Tumors of the Skin: A 12-Year Perspective. Cancers, 2022, 14, 998.	1.7	4
143	Chemotherapy of pancreatic solid pseudopapillary carcinoma – A case report and a literature review. Cancer Treatment Communications, 2016, 7, 47-51.	0.4	3
144	Effect of Everolimus on Heterogenous Renal Cancer Cells Populations Including Renal Cancer Stem Cells. Stem Cell Reviews and Reports, 2018, 14, 385-397.	5.6	3

#	ARTICLE	IF	CITATIONS
145	TP53-Deficient Angiosarcoma Expression Profiling in Rat Model. <i>Cancers</i> , 2020, 12, 1525.	1.7	3
146	Association of breathing patterns and quality of life in patients with nasal obstruction. <i>Otolaryngologia Polska</i> , 2018, 72, 11-15.	0.2	3
147	Treatment of Locally Advanced Merkel Cell Carcinoma – A Multi-Center Study. <i>Cancers</i> , 2022, 14, 422.	1.7	3
148	Nasopharyngeal chordoma in a patient with a severe form of sleep-disordered breathing: A case report. <i>Oncology Letters</i> , 2015, 10, 1805-1809.	0.8	2
149	The preferential nNOS inhibitor 7-nitroindazole and the non-selective one NG-nitro-L-arginine methyl ester administered alone or jointly with L-DOPA differentially affect motor behavior and monoamine metabolism in sham-operated and 6-OHDA-lesioned rats. <i>Brain Research</i> , 2015, 1625, 218-237.	1.1	2
150	Contribution of the nitric oxide donor molsidomine and the antiparkinsonian drug L-DOPA to the modulation of the blood pressure in unilaterally 6-OHDA-lesioned rats. <i>Pharmacological Reports</i> , 2017, 69, 29-35.	1.5	2
151	Preoperative hypofractionated radiotherapy (RT) combined with chemotherapy in primary marginally resectable high grade soft tissue sarcomas (STS) of extremities or trunk wall: Interim analysis of prospective phase II clinical trial. <i>Annals of Oncology</i> , 2018, 29, viii585-viii586.	0.6	2
152	Biomarkers defining probability of receiving second-line targeted therapy in metastatic renal cell carcinoma. <i>Medical Oncology</i> , 2018, 35, 91.	1.2	2
153	Hyperpolarized ¹³ C tracers: Technical advancements and perspectives for clinical applications. <i>Biocybernetics and Biomedical Engineering</i> , 2021, 41, 1466-1485.	3.3	2
154	Comparison of the efficacy and toxicity of anti-PD-1 monoclonal antibodies (nivolumab versus) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 38 2021, 39, e21514-e21514.	0.8	2
155	Mechanisms of melanoma resistance to treatment with BRAF and MEK inhibitors. <i>Nowotwory</i> , 2019, 69, 133-141.	0.1	2
156	Clear cell sarcoma. <i>Oncology in Clinical Practice</i> , 2019, 14, 354-363.	0.1	2
157	Mucosal melanoma – clinical presentation and treatment based on a case series. <i>Oncology in Clinical Practice</i> , 2019, 15, 223-230.	0.1	2
158	Radioterapia chorych na czerniaka. <i>Oncology in Clinical Practice</i> , 2020, 15, 310-319.	0.1	2
159	Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients. <i>Cancers</i> , 2022, 14, 2123.	1.7	2
160	The Role of Diabetes in Molecular Pathogenesis of Cancer. <i>Current Signal Transduction Therapy</i> , 2015, 10, 10-16.	0.3	1
161	Long-term parental satisfaction with adenotonsillectomy: a population study. <i>Sleep and Breathing</i> , 2015, 19, 1425-1429.	0.9	1
162	Intermittent sunitinib is an effective renal carcinoma treatment. <i>Nature Reviews Urology</i> , 2017, 14, 264-266.	1.9	1

#	ARTICLE	IF	CITATIONS
163	Rozpoznanie i leczenie limfangioleiomiomatozy (LAM) z grupy PEComa. <i>Oncology in Clinical Practice</i> , 2021, 17, 28-41.	0.1	1
164	Treatment beyond progression with immune checkpoint inhibitors in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21541-e21541.	0.8	1
165	Clear Cell Renal Cell Cancer Tumor-Propagating Cells: Molecular Characteristics. <i>Current Signal Transduction Therapy</i> , 2014, 8, 229-239.	0.3	1
166	Summary of immunotherapy efficacy ordered in accordance with drug reimbursement program in melanoma patients. <i>Oncology in Clinical Practice</i> , 2020, 16, 56-68.	0.1	1
167	The regulation of clear cell renal cancer cells proliferation and tyrosine kinase inhibitors responsiveness by tumor micro-environmental factors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 488-488.	0.8	1
168	Porównanie po średnie wyników w leczeniu chorych na zaawansowane/przerzutowe czerniaki za pomocą... niwolumabu lub pembrolizumabu – analiza wielośrodkowa. <i>Oncology in Clinical Practice</i> , 2020, 16, 295-300.	0.1	1
169	The analysis of treatment sequencing and clinical outcomes in BRAF-positive and BRAF-negative unresectable/metastatic melanoma patients treated with systemic therapies in routine practice. <i>Annals of Oncology</i> , 2018, 29, viii451.	0.6	0
170	The analysis of current treatment outcomes in melanoma patients with brain metastases. <i>Annals of Oncology</i> , 2019, 30, v555-v556.	0.6	0
171	The Long-Term Outcomes of Intensive Combined Therapy of Adult Patients with Localised Synovial Sarcoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 3129.	1.0	0
172	Systemic treatment of patients with inoperable and metastatic Merkel cell carcinoma: A multicenter study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21521-e21521.	0.8	0
173	Immunotherapy Resistance Mechanisms in Renal Cell Cancer. <i>Current Signal Transduction Therapy</i> , 2014, 8, 247-255.	0.3	0
174	Treatment obstacles for metastatic clear cell renal cell carcinoma of Fuhrman grade IV and with sarcomatoid histologies.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15604-e15604.	0.8	0
175	Molecular factors regulating clear cell renal cancer cells' fate: Implications for tyrosine kinase inhibitors responsiveness and toxicities.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15577-e15577.	0.8	0
176	Okręgowy st, 2013: zalecenia terapeutyczne w leczeniu systemowym rozlanego raka nerkowokomarkowego. <i>Nowotwory</i> , 2014, 64, 443-453.	0.1	0
177	Molecular events regulating clear cell renal cell cancer resistance to tyrosine kinase inhibitors.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15600-e15600.	0.8	0
178	Gene expression profiling of primary and metastatic renal cell carcinoma tumor initiating cells.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16091-e16091.	0.8	0
179	Leczenie pembrolizumabem w pierwszej linii w uogólnionym czerniaku z wykrytą... mutacją... w kodonie V600 genu BRAF oraz z izolowan... progresją... choroby w młodym wieku. <i>Oncology in Clinical Practice</i> , 2019, 14, 28-33.	0.1	0
180	Clinicopathological prognostic and predictive factors of malignant peripheral nerve sheath tumors (MPNST) survival and treatment efficacy.. <i>Journal of Clinical Oncology</i> , 2019, 37, e22537-e22537.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Correlation of immunity-related adverse events with survival and response to anti-PD-1 treatment in patients with metastatic melanoma.. Journal of Clinical Oncology, 2020, 38, e15164-e15164.	0.8	0
182	Prognostic and predictive factors for the outcomes of clear cell sarcoma (CCS) multidisciplinary treatment: The role of lymph node involvement.. Journal of Clinical Oncology, 2020, 38, e23554-e23554.	0.8	0